PTC Therapeutics GAAP EPS of -$1.20 beats by $0.07, revenue of $210.12M beats by $46.3M

2024-04-26 04:52

PTC Therapeutics press release (NASDAQ:PTCT): Q1 GAAP EPS of -$1.20 beats by $0.07.
Revenue of $210.12M (-4.7% Y/Y) beats by $46.3M.
2024 Outlook: PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million.
PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between $740 and $835 million.
PTC anticipates Non-GAAP R&D and SG&A expense for full year 2024 to be between $660 and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.
PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expense.

More on PTC Therapeutics